Literature DB >> 18067603

Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor.

H A A M van Vliet1, R M Bertina, A E A Dahm, F R Rosendaal, J Rosing, P Morten Sandset, F M Helmerhorst.   

Abstract

BACKGROUND: Oral contraceptives (OC) containing different types of progestogens induce different sensitivities to activated protein C (APC) measured with the thrombin generation-based APC-resistance test. These differences in APC resistance may be the biological explanation for the differences in thrombotic risk of the various pills. The mechanistic basis of APC resistance observed in OC users is unknown. Our objective was to study the effect of OC on the two main determinants of the APC-resistance test, free protein S and free tissue factor pathway inhibitor (TFPI). PATIENTS/
METHODS: We measured free protein S and free TFPI in 156 users of various types of OC.
RESULTS: Users of desogestrel-containing OC, known to double the risk of thrombosis compared with levonorgestrel-containing OC, had lower free protein S (24 vs. 33 U dL(-1)) and TFPI free antigen (2.9 vs. 3.6 ng mL(-1)) levels than users of OC containing levonorgestrel. Women using cyproterone acetate-containing OC, known to confer a high thrombotic risk, had the lowest free protein S (19 U dL(-1)) and free TPFI antigen (2.5 ng mL(-1)) levels. Users of OC containing drospirenone had lower free protein S (23 U dL(-1)) and TFPI antigen levels (3.2 ng mL(-1)) than users of levonorgestrel-containing OC. Low free protein S and low free TFPI antigen levels were associated with an increased resistance to APC, an established risk factor for thrombosis.
CONCLUSIONS: This study observed that the differences in APC resistance induced by OC containing different progestogens can at least in part be explained by different effects of OC on free protein S and TFPI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18067603     DOI: 10.1111/j.1538-7836.2007.02863.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

Review 1.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

2.  Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains.

Authors:  Amit Prabhakar; Tathagata Chatterjee; Nitin Bajaj; Tarun Tyagi; Anita Sahu; Neha Gupta; Babita Kumari; Velu Nair; Bhuvnesh Kumar; Mohammad Zahid Ashraf
Journal:  Blood Adv       Date:  2019-11-26

3.  Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.

Authors:  Jacques E Rossouw; Karen C Johnson; Mary Pettinger; Mary Cushman; Per Morten Sandset; Lewis Kuller; Frits Rosendaal; Jan Rosing; Sylvia Wasserthal-Smoller; Lisa W Martin; Joann E Manson; Kamakshi Lakshminarayan; Jose G Merino; John Lynch
Journal:  Stroke       Date:  2012-02-23       Impact factor: 7.914

4.  Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.

Authors:  Karen C Johnson; Aaron K Aragaki; Rebecca Jackson; Alex Reiner; Per Morten Sandset; Jan Rosing; Anders E A Dahm; Frits Rosendaal; JoAnn E Manson; Lisa W Martin; Simin Liu; Lewis H Kuller; Mary Cushman; Jacques E Rossouw
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

Review 5.  Metabolic effects of contraceptive steroids.

Authors:  Regine Sitruk-Ware; Anita Nath
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 6.  Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.

Authors:  S Mantha; R Karp; V Raghavan; N Terrin; K A Bauer; J I Zwicker
Journal:  BMJ       Date:  2012-08-07

7.  Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women.

Authors:  Rossella E Nappi; Anna Maria Paoletti; Annibale Volpe; Luca Chiovato; Brandon Howard; Herman Weiss; Nancy Ricciotti
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-06-13       Impact factor: 1.848

Review 8.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12

9.  [Venous thromboembolic disease in the region of Sidi Bel Abbes, Algeria: frequency and risk factors].

Authors:  Nourelhouda Chalal; Abbassia Demmouche
Journal:  Pan Afr Med J       Date:  2013-10-10

10.  Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis.

Authors:  Marija Glisic; Sara Shahzad; Stergiani Tsoli; Mahmuda Chadni; Eralda Asllanaj; Lyda Z Rojas; Elizabeth Brown; Rajiv Chowdhury; Taulant Muka; Oscar H Franco
Journal:  Eur J Prev Cardiol       Date:  2018-05-10       Impact factor: 7.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.